HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics




HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

— First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities —

— Unique, highly potent PI3K/PIKK inhibitor payload optimized to exploit antibody-conjugate advantages, with directed delivery and low plasma exposure of free payload —

— Preclinical data shows robust antitumor activity with synergistic and bystander killing effects —

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces preclinical data for HMPL-A251 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 22–26, 2025, in Boston, USA. HMPL-A251 is a first-in-class PI3K/AKT/mTOR (“PAM”)-HER2 Antibody-Targeted Therapy Conjugate (“ATTC”) comprising of a highly selective and potent PI3K/PIKK inhibitor payload linked to a humanized anti-HER2 IgG1 antibody, via a cleavable linker.

HER2 is a well-established therapeutic target. HER2 overexpression is found in a variety of cancer types and often associated with poor prognosis. As a key downstream signaling pathway of HER2, the PAM pathway contributes significantly to the resistance against HER2-targeting treatments when altered. HMPL-A251 is innovatively designed to leverage the synergy between HER2 targeting and PAM pathway inhibition to address limitations of traditional toxin-based antibody-drug conjugates (“ADCs”) and standalone PAM inhibitors.

In vitro, the PI3K/PIKK inhibitor payload exhibited high potency, selectivity, and broad anti-tumor activity across a panel of 130 tumor cell lines. By conjugating this potent payload with an anti-HER2 antibody via a hydrophilic linker, the ATTC compound HMPL-A251, upon binding to the HER2-positive target cells, undergoes rapid internalization, lysosomal trafficking, payload release, and inhibition of PAM and PIKK signaling, inducing tumor cell apoptosis. HMPL-A251 demonstrated HER2-dependent antitumor activity in vitro, potently inhibiting HER2-positive tumor cell growth regardless of PAM pathway alterations, with moderately reduced activity in HER2-low, PAM-altered cell lines. HMPL-A251 also demonstrated a bystander effect on HER2-null cells when co-cultured with HER2-positive cells.

Unlike toxin-based ADCs, which often face challenges with toxicity related to their cytotoxic payloads, ATTCs are designed to prioritize tumor-specific delivery of a pathway-modulating payload, enhancing safety for long-term use and enabling potential frontline combinations with chemotherapy. In vivo, HMPL-A251 demonstrated superior anti-tumor efficacy and tolerability as compared to the naked antibody and payload administered together. A single intravenous dose of HMPL-A251 induced tumor regression across multiple models including HER2-positive and HER2-low models with or without PAM alteration. Efficacy correlated strongly with payload concentration and target inhibition in tumor tissue. Notably, when benchmarked against T-DXd (trastuzumab deruxtecan, a HER2-directed ADC), HMPL-A251 achieved superior or comparable efficacy at equivalent doses in most tested models. Moreover, payload-based toxicities are expected to be low, as the plasma exposure of free payload was much lower than for HMPL-251, with a mass ratio of less than 1:500,000.

“We are excited to share the progress of HMPL-A251, the first candidate from our ATTC platform. It represents a potentially significant leap forward in addressing the limitations of toxin-based ADCs and narrow therapeutic window of systemic PAM inhibitors. By combining selective PI3K/PIKK inhibition with precise HER2 targeting, HMPL-A251 achieves potent antitumor effects while maintaining a favorable safety profile,” said Dr Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED. “The compelling preclinical data presented underscore its potential to redefine treatment for a wide spectrum of cancers, and we are excited to advance HMPL-A251 as well as more ATTC drug candidates toward clinical trials.”

HUTCHMED plans to initiate global clinical trials for HMPL-A251 around the end of 2025, followed by multiple global Investigational New Drug (IND) filings for more ATTC candidates in 2026.

About the ATTC platform

HUTCHMED’s Antibody-Targeted Therapy Conjugate platform represents a next-generation approach to precision oncology, combining monoclonal antibodies with proprietary small-molecule inhibitor payloads to deliver dual mechanisms of action. Unlike traditional cytotoxin-based ADCs, ATTCs combine targeted therapies to achieve synergistic anti-tumor activity and durable responses in preclinical models, outperforming standalone antibody or small-molecule inhibitor components in efficacy and safety.

Built on over 20 years of targeted therapy expertise, the platform enables development of drug candidates for diverse cancer types. By leveraging antibody-guided delivery and tumor-specific payload release, ATTCs improve the accessibility to tumors and reduce off-tumor toxicity. This overcomes challenges of traditional small-molecule inhibitors, ensures safer long-term use, and supports combinations with chemotherapy and immunotherapy, unlocking potential for early-line treatments.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of HMPL-A251 and other drug candidates from the ATTC platform, the further clinical development for HMPL-A251 and other drug candidates from the ATTC platform, its expectations as to whether any studies on HMPL-A251 and other drug candidates from the ATTC platform would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of HMPL-A251 and other drug candidates from the ATTC platform, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of HMPL-A251 other drug candidates from the ATTC platform for a targeted indication, and the sufficiency of funding. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

Investor Enquiries +852 2121 8200 / ir@hutch-med.com
   
Media Enquiries  
FTI Consulting – +44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Alex Shaw +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
Brunswick – Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
   
Panmure Liberum Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden +44 20 7886 2500
   
Cavendish Joint Broker
Geoff Nash / Nigel Birks +44 20 7220 0500
   
Deutsche Numis Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith +44 20 7260 1000

HearAdvisor Announces New Guide on the Best Hearing Aids and Earplugs of 2025 with Expert Choice Awards

HearAdvisor Announces New Guide on the Best Hearing Aids and Earplugs of 2025 with Expert Choice Awards




HearAdvisor Announces New Guide on the Best Hearing Aids and Earplugs of 2025 with Expert Choice Awards

Rockford, Il, Oct. 22, 2025 (GLOBE NEWSWIRE) — HearAdvisor, an independent audio performance lab, today announced the winners of its 2025 Expert Choice Awards, recognizing the best hearing aids and earplugs of the year. Now in its third year, the awards highlight products that deliver exceptional sound quality and performance based on rigorous objective lab testing. HearAdvisor is the only lab worldwide offering independent, data-driven comparisons for hearing aids and concert earplugs, with testing completed on more than 100 hearing aids and 30 earplugs.

HearAdvisor Announces Best Hearing Aids and Earplugs of 2025 with Expert Choice Awards

HearAdvisor is the only lab worldwide offering independent, data-driven comparisons for hearing aids and concert earplugs, with testing completed on more than 100 hearing aids and 30 earplugs.

New for 2025:

  • Blind Listening Test: Visitors can now compare the sound of 100+ hearing aids to learn which products make it easier for them to hear speech in noise.
  • Lab Notes: Product pages now include device setup and programming details.

Featured Winners

When the FDA finalized the over-the-counter (OTC) hearing aid category in 2022, the goal was better access to high-quality, affordable hearing technology. While lab-testing results for non-premium OTC products were modest at first, HearAdvisor’s 2025 tests reveal that some budget OTC devices are finally delivering on that goal.

With prices ranging from $599 to $1,299, these are some of this year’s standout OTC products: Elehear Beyond Pro, Lexie B2 Plus, Lucid Engage, Lucid Tala, and Yeasound RIC800. HearAdvisor also highlights hearing protection. For example, Etymotic Research ER20XS earned top marks for sound quality and reduction.

Quotes from HearAdvisor

“We’re seeing better and better performance in OTC hearing aids, even for those on a small budget.” – Dr. Abram Bailey, AuD, Co-Founder and Business Development

“Our mission is to make hearing technology more transparent and accessible through rigorous and objective lab testing.” – Dr. Andy Sabin, PhD, Scientific Advisor

“This is our third year testing, and we continue to be inspired by the feedback we receive from the community. It reassures and motivates us to keep going, whether through new Lab Notes on product pages or our new listening test.” – Dr. Steve Taddei, AuD, Co-Founder and Lab Director

Learn More

The full list of 2025 Expert Choice Award winners is available at HearAdvisor.com/awards.

About HearAdvisor

Founded in 2022, HearAdvisor provides objective, science-based evaluations of hearing technology. HearAdvisor aims to empower people to make more informed decisions about hearing health. Learn more at HearAdvisor.com.

HearAdvisor Announces Best Hearing Aids and Earplugs of 2025 with Expert Choice Awards

HearAdvisor Lab Director Dr Steve Taddei securely fitting Loop Earplugs on the acoustic test manikin.

Press inquiries

HearAdvisor
https://www.hearadvisor.com/
Dr Steve Taddei
steve@hearadvisor.com 

A video accompanying this announcement is available at https://www.youtube.com/embed/-wSoGyqL9r0

HearAdvisor Announces New Guide on the Best Hearing Aids and Earplugs of 2025 with Expert Choice Awards

HearAdvisor Announces New Guide on the Best Hearing Aids and Earplugs of 2025 with Expert Choice Awards




HearAdvisor Announces New Guide on the Best Hearing Aids and Earplugs of 2025 with Expert Choice Awards

Rockford, Il, Oct. 22, 2025 (GLOBE NEWSWIRE) — HearAdvisor, an independent audio performance lab, today announced the winners of its 2025 Expert Choice Awards, recognizing the best hearing aids and earplugs of the year. Now in its third year, the awards highlight products that deliver exceptional sound quality and performance based on rigorous objective lab testing. HearAdvisor is the only lab worldwide offering independent, data-driven comparisons for hearing aids and concert earplugs, with testing completed on more than 100 hearing aids and 30 earplugs.

HearAdvisor Announces Best Hearing Aids and Earplugs of 2025 with Expert Choice Awards

HearAdvisor is the only lab worldwide offering independent, data-driven comparisons for hearing aids and concert earplugs, with testing completed on more than 100 hearing aids and 30 earplugs.

New for 2025:

  • Blind Listening Test: Visitors can now compare the sound of 100+ hearing aids to learn which products make it easier for them to hear speech in noise.
  • Lab Notes: Product pages now include device setup and programming details.

Featured Winners

When the FDA finalized the over-the-counter (OTC) hearing aid category in 2022, the goal was better access to high-quality, affordable hearing technology. While lab-testing results for non-premium OTC products were modest at first, HearAdvisor’s 2025 tests reveal that some budget OTC devices are finally delivering on that goal.

With prices ranging from $599 to $1,299, these are some of this year’s standout OTC products: Elehear Beyond Pro, Lexie B2 Plus, Lucid Engage, Lucid Tala, and Yeasound RIC800. HearAdvisor also highlights hearing protection. For example, Etymotic Research ER20XS earned top marks for sound quality and reduction.

Quotes from HearAdvisor

“We’re seeing better and better performance in OTC hearing aids, even for those on a small budget.” – Dr. Abram Bailey, AuD, Co-Founder and Business Development

“Our mission is to make hearing technology more transparent and accessible through rigorous and objective lab testing.” – Dr. Andy Sabin, PhD, Scientific Advisor

“This is our third year testing, and we continue to be inspired by the feedback we receive from the community. It reassures and motivates us to keep going, whether through new Lab Notes on product pages or our new listening test.” – Dr. Steve Taddei, AuD, Co-Founder and Lab Director

Learn More

The full list of 2025 Expert Choice Award winners is available at HearAdvisor.com/awards.

About HearAdvisor

Founded in 2022, HearAdvisor provides objective, science-based evaluations of hearing technology. HearAdvisor aims to empower people to make more informed decisions about hearing health. Learn more at HearAdvisor.com.

HearAdvisor Announces Best Hearing Aids and Earplugs of 2025 with Expert Choice Awards

HearAdvisor Lab Director Dr Steve Taddei securely fitting Loop Earplugs on the acoustic test manikin.

Press inquiries

HearAdvisor
https://www.hearadvisor.com/
Dr Steve Taddei
steve@hearadvisor.com 

A video accompanying this announcement is available at https://www.youtube.com/embed/-wSoGyqL9r0

CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025

CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025




CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025

MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2025 financial and operating results after market close on Wednesday, Nov. 5, 2025. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.

A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1- 877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers 
CVRx, Inc. 
763-416-2853
emeyers@cvrx.com

CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025

CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025




CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025

MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2025 financial and operating results after market close on Wednesday, Nov. 5, 2025. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.

A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1- 877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers 
CVRx, Inc. 
763-416-2853
emeyers@cvrx.com

Clover Health to Participate in Upcoming 2025 UBS Global Healthcare Conference

Clover Health to Participate in Upcoming 2025 UBS Global Healthcare Conference




Clover Health to Participate in Upcoming 2025 UBS Global Healthcare Conference

WILMINGTON, Del., Oct. 22, 2025 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 UBS Global Healthcare Conference on Tuesday, November 11, 2025, at 11:00 a.m. Eastern Time.

A live webcast and replay of the presentation will be accessible on Clover Health’s investor relations website at https://investors.cloverhealth.com/.

About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health’s Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, Congestive Heart Failure, and Chronic Obstructive Pulmonary Disease as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

Investor Relations:
Ryan Schmidt
investors@cloverhealth.com

Press Inquiries:
press@cloverhealth.com

Clover Health to Participate in Upcoming 2025 UBS Global Healthcare Conference

Clover Health to Participate in Upcoming 2025 UBS Global Healthcare Conference




Clover Health to Participate in Upcoming 2025 UBS Global Healthcare Conference

WILMINGTON, Del., Oct. 22, 2025 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 UBS Global Healthcare Conference on Tuesday, November 11, 2025, at 11:00 a.m. Eastern Time.

A live webcast and replay of the presentation will be accessible on Clover Health’s investor relations website at https://investors.cloverhealth.com/.

About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health’s Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, Congestive Heart Failure, and Chronic Obstructive Pulmonary Disease as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

Investor Relations:
Ryan Schmidt
investors@cloverhealth.com

Press Inquiries:
press@cloverhealth.com

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease




Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sjögren’s disease. The study was conducted by Vor Bio’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331).

During the webcast, Vor Bio management, joined by Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results from the trial.

Webcast Details:

Date: Tuesday, October 28, 2025
Time: 4:30 PM Eastern Time

Access: 

  • Listen Only: Listeners can register for the webcast via this LINK
  • Listen and Live Q&A: Analysts or investors wishing to participate in the Q&A session should use this LINK

Replay: A replay of the webcast will be available via the investor section of the Company’s website at https://ir.vorbio.com/events-presentations/ approximately two hours after the call’s conclusion and will remain available for a period of 30 days.

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

Sarah Spencer
investors@vorbio.com

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease




Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sjögren’s disease. The study was conducted by Vor Bio’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331).

During the webcast, Vor Bio management, joined by Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results from the trial.

Webcast Details:

Date: Tuesday, October 28, 2025
Time: 4:30 PM Eastern Time

Access: 

  • Listen Only: Listeners can register for the webcast via this LINK
  • Listen and Live Q&A: Analysts or investors wishing to participate in the Q&A session should use this LINK

Replay: A replay of the webcast will be available via the investor section of the Company’s website at https://ir.vorbio.com/events-presentations/ approximately two hours after the call’s conclusion and will remain available for a period of 30 days.

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

Sarah Spencer
investors@vorbio.com

Generation Bio Announces CEO Transition

Generation Bio Announces CEO Transition




Generation Bio Announces CEO Transition

• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company’s Board of Directors

• Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President

CAMBRIDGE, MASS., Oct. 22, 2025 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that Geoff McDonough, MD will step down as Chief Executive Officer and President, and will Chair the company’s Board of Directors. The Board has appointed Yalonda Howze, JD, as Interim Chief Executive Officer and President. Ms. Howze has served as the Company’s Chief Legal Officer since joining in April 2023. Jason Rhodes will step down as Chair of the Board and will remain a Board Director. These changes will be effective October 31, 2025.

“Geoff has been instrumental in building Generation Bio, and we look forward to his leadership as Board Chair.” said Jason Rhodes, former Board Chair of Generation Bio. “We have the highest confidence in Yalonda’s ability to lead Generation Bio in her new role during this time of transition for the company.”

About Generation Bio
Generation Bio is a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. The company is developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. Generation Bio’s innovative approach leverages cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) to T cells. This combination of selective delivery and an intracellular, genetically precise mechanism of target engagement could unlock a series of high-value, historically undruggable disease-driving genes in autoimmunity.

For more information, please visit www.generationbio.com.

Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the company, including statements about the company’s leadership transition, the company’s strategic alternatives process, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties as to the company’s ability to successfully pursue a strategic alternative transaction on attractive terms, or at all; whether the chief executive officer transition will be successful; as well as the other risks and uncertainties set forth in the “Risk Factors” section of the company’s most recent annual report on Form 10-K and quarterly report on Form 10-Q, which are on file with the Securities and Exchange Commission, and in subsequent filings the company may make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof. The company anticipates that subsequent events and developments will cause the company’s views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date on which they were made.

Investors and Media Contact
Kevin Conway
Generation Bio
investors@generationbio.com
(857) 371-4721